President Trump is reportedly preparing to nominate Heidi Overton as the next commissioner of the Food and Drug Administration (FDA), according to multiple media reports. Overton is a senior conservative policy adviser with extensive experience in health care policy and federal regulatory issues.
Overton currently serves as deputy director of the White House Domestic Policy Council, where she has helped shape health care policy during President Trump’s second term. Her views have also drawn attention from members of the “Make America Healthy Again” movement, some of whom have criticized her policy positions and relationship with Health Secretary Robert F. Kennedy Jr.
She earned her medical degree from the University of New Mexico School of Medicine and a doctorate in clinical research from the Johns Hopkins Bloomberg School of Public Health. During her time at Johns Hopkins, Overton worked with former FDA Commissioner Marty McCulley, who was later removed from office by President Trump amid controversy.
The former FDA commissioner and other political appointees faced criticism over several regulatory decisions, including policies involving rare-disease drugs. Those decisions frustrated patients and pharmaceutical companies and drew opposition from tobacco industry representatives, public health advocates, anti-abortion groups, and federal officials. According to The Wall Street Journal, Overton was a strong defender of the former commissioner during his tenure.
Before joining the White House, Overton worked on health policy at the America First Policy Institute, a conservative think tank previously led by Brooke Rollins, who now serves as President Trump’s Secretary of Agriculture.
Heidi Overton’s FDA Policy Positions
Overton’s views on abortion and reproductive health are expected to receive significant attention if she is nominated to lead the FDA. Despite extensive research showing that abortion pills are highly safe, Overton has written that abortion is “corrosive” to women and argued that abortion medications pose serious risks.
Medical experts generally consider medication abortion safer than several common medical procedures and significantly safer than childbirth. Nevertheless, Overton’s position aligns with broader conservative efforts to persuade the FDA to limit access to abortion drugs.
If confirmed, Heidi Overton would oversee the FDA’s regulation of prescription medicines, medical devices, vaccines, food safety, and other products affecting public health. Her nomination could make abortion-pill access, pharmaceutical regulation, and the future direction of the agency central issues in the confirmation process.
Source: arstechnica.com